Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lazabemide SCHEMBL20769840 | 1.00 | MAOB (1.00) | MAOBCYP1A2TSHRNFKB1MEN1 | |
| Lazabemide SCHEMBL29710899 | 1.00 | MAOB (1.00) | MAOBCYP1A2TSHRNFKB1MEN1 | |
| Lazabemide SCHEMBL29389663 | 0.98 | MAOB (0.97) | MAOBCYP1A2TSHRNFKB1MEN1 | |
| Lazabemide SCHEMBL1230476 | 0.98 | MAOB (0.97) | MAOBCYP1A2TSHRNFKB1MEN1 | |
| SCHEMBL8973342 | 0.90 | MAOB (0.81) | MAOBMEN1KMT2AEGLN1MAOA | |
| SCHEMBL19835607 | 0.86 | MAOB (0.76) | MAOBMALT1EGLN1MAOANPC1 | |
| SCHEMBL8396789 | 0.83 | MAOB (0.71) | MAOBKMT2AEGLN1MAOANPC1 | |
| SCHEMBL29459609 | 0.83 | MAOB (0.71) | MAOBEGLN1MAOANPC1RAB9A | |
| SCHEMBL14329887 | 0.83 | MAOB (0.71) | MAOBEGLN1MAOANPC1RAB9A | |
| SCHEMBL29262574 | 0.83 | MAOB (0.71) | MAOBEGLN1MAOANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2905 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | claimed |
| EP-3810105-A2 | NEW USE OF INHIBITORS OF MONOAMINE OXIDASE TYPE B | Istituto di Ricerca Pediatrica Citta della Speranza (IT) | 2021-04-28 | — | — | EP | claimed |
| EP-3716963-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD1 BINDING ANTAGONIST | Epiaxis Therapeutics Pty Ltd (AU) | 2020-10-07 | — | — | EP | claimed |
| CN-111655247-A | Enhancing T cell function and treating T cell dysfunction disorders with a combination of a LSD inhibitor and a PD1 binding antagonist | 艾比克斯治疗私人有限公司 | 2020-09-11 | — | — | CN | claimed |
| US-20200188388-A1 | METHODS AND COMPOSITIONS FOR POTENTIATING CNS DRUGS AND REDUCING THEIR SIDE EFFECTS | SYNNERVA LTD. (IL) | 2020-06-18 | — | — | US | claimed |
| WO-2019244014-A2 | NEW USE OF INHIBITORS OF MONOAMINE OXIDASE TYPE B | ISTITUTO DI RICERCA PEDIATRICA CITTÀ DELLA SPERANZA (IT) | 2019-12-26 | — | — | WO | claimed |
| EP-3562477-A1 | METHODS AND COMPOSITIONS FOR POTENTIATING CNS DRUGS AND REDUCING THEIR SIDE EFFECTS | Rvx Therapeutics Ltd. (IL) | 2019-11-06 | — | — | EP | claimed |
| CN-110337289-A | Methods and compositions for enhancing CNS drugs and reducing their side effects | RVX疗法有限公司 | 2019-10-15 | — | — | CN | claimed |
| US-10258738-B2 | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like | CHRONO THERAPEUTICS INC. (US) | 2019-04-16 | — | — | US | claimed |
| EP-0814789-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOAMINE OXIDASE B INHIBITORS | R.P. Scherer Limited (GB) | 1998-01-07 | — | — | EP | claimed |
| US-5668117-A | NERVOUS SYSTEM DISORDERS USING AROMATIC ACID COMPOUNDS | SECANT PHARMA, LLC | 1997-09-16 | — | — | US | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| JP-H08512055-A | — | — | 1996-12-17 | — | — | JP | claimed |
| WO-1996026720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOAMINE OXIDASE B INHIBITORS | R.P. SCHERER LIMITED (GB) | 1996-09-06 | — | — | WO | claimed |
| EP-0707446-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO, Howard, K. (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995001096-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1995-01-12 | — | — | WO | claimed |
| EP-0520325-A1 | Use of monoamine oxidase-B-inhibitors for the prevention and treatment of withdrawal symptoms after alcohol and drug abuse | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1992-12-30 | — | — | EP | claimed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | claimed |